-Reuters
eFFECTOR Therapeutics Provides Clinical Data Update For Zotatifin, General Corporate Update
Zotatifin program update as of December 15, 2022:
In the cohort (n=7) receiving zotatifin, fulvestrant and abemaciclib (ECBF+A), two patients experienced confirmed PRs, and a third patient had stable disease